Free Trial

Oncternal Therapeutics (ONCT) Stock Forecast & Price Target

$9.41
+0.20 (+2.17%)
(As of 05/28/2024 ET)

Oncternal Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 3 Analyst Ratings

Consensus Price Target

$28.33
201.09% Upside
High Forecast$40.00
Average Forecast$28.33
Low Forecast$19.00
TypeCurrent Forecast
5/29/23 to 5/28/24
1 Month Ago
4/29/23 to 4/28/24
3 Months Ago
2/28/23 to 2/28/24
1 Year Ago
5/29/22 to 5/29/23
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.33$31.33$69.00$115.33
Forecasted Upside201.09% Upside328.13% Upside765.99% Upside701.26% Upside
Get Oncternal Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.

ONCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ONCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oncternal Therapeutics Stock vs. The Competition

TypeOncternal TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.70
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside211.70% Upside831.01% Upside10.69% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$28.00 ➝ $19.00+132.27%
12/4/2023Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$40.00+497.19%
9/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Watsek
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$26.00+343.84%
4/4/2023Brookline Capital Acquisition
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
4/4/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
4/4/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:09 PM ET.

ONCT Frequently Asked Questions

What is Oncternal Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Oncternal Therapeutics is $28.33, with a high forecast of $40.00 and a low forecast of $19.00. The consensus rating for Oncternal Therapeutics stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for ONCT. Learn more on ONCT's analyst rating history.

Do Wall Street analysts like Oncternal Therapeutics more than its competitors?

Analysts like Oncternal Therapeutics less than other "medical" companies. The consensus rating score for Oncternal Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.70. Learn more on how ONCT compares to other companies.

Does Oncternal Therapeutics's stock price have much upside?

According to analysts, Oncternal Therapeutics's stock has a predicted upside of 309.92% based on their 12-month stock forecasts.

What analysts cover Oncternal Therapeutics?

Oncternal Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:ONCT) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners